ReviewACS applied materials & interfaces2025
The Nanocarrier Landscape─Evaluating Key Drug Delivery Vehicles and Their Capabilities: A Translational Perspective.
Review in ACS applied materials & interfaces, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Nanoparticle based drug delivery systems improve antimalarial efficacy and vaccine performance in African research and clinical settings.Discover nano · 2026Review
- Biomimetic photodynamic nanoparticles exert anti-tumor therapy by inducing ferroptosis in non-small cell lung cancer.Materials today. Bio · 2026Article
- Nanomedicine in the Topical Management of Vulvovaginal Candidiasis: An Overview of In Vivo Data.Journal of fungi (Basel, Switzerland) · 2026Review
- Liposome-Mediated Bacterial Ferroptosis-like Death: A Novel Paradigm for Antimicrobial Therapy.Antibiotics (Basel, Switzerland) · 2026Review
- Nanotechnology-Enabled Strategies to Overcome Antibiotic Resistance in Respiratory Infections: Mechanisms, Platforms, and Translational Challenges.Biomedicines · 2026Review
- Hydrophobically Modified Chitosan in Biomedical Applications: Great Expectations vs. Translational Reality.Polymers · 2026Article
- Protein-Based Nanomaterials for Cancer Therapy: A Comparative and Translational Perspective.Pharmaceutics · 2026Review
- EnterohemorrhagicACS omega · 2026Article
- Iron-Based Nanoparticles as Delivery Tools.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Stimuli-Responsive Carbon Nanotubes for On-Demand Cancer Therapy: A Review.AAPS PharmSciTech · 2026Review
- Applications of Carbon Dots and Graphene Quantum Dots in Treatment of Diabetes.Molecules (Basel, Switzerland) · 2026Review
- AI-driven nanomedicine for cancer theranostics.Molecular cancer · 2026Review
- Bacterial secondary metabolites as resistance-modifying adjuvants: microbial origins, molecular mechanisms, and translational relevance.Frontiers in microbiology · 2026Review
- Emerging Nanocarrier Strategies for Optimized Drug Delivery in the Treatment of Primary Bone Cancer.Oncology research · 2026Review
- Review
- Quo Vadis translational neuroscience?Translational neuroscience · 2026Review
- Cellular and molecular mechanisms of thrombosis and thrombus-targeted thrombolytic strategies.Materials today. Bio · 2025Review
- Targeting Multiple Pathophysiological Axes in COPD: Nanomaterial Advances.International journal of nanomedicine · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The field of nanomedicine is currently in a revolutionary phase, propelled by the significant potential of nanoparticles, which offer several advantages over traditional drug delivery systems. The purpose of this paper is to aggregate contemporary knowledge of nanoparticles developed and applied in drug delivery across major disease classes. Accordingly, we offer, through a thorough search of the literature, a comprehensive overview of the prevalent nanoparticles used in drug delivery systems, covering polymeric, lipid-based, inorganic, and carbon-based nanoparticles, and discuss their advantages and limitations. This work primarily focuses on studies published in the last 5 years, aiming to provide an up-to-date assessment of the critical nanoparticles in drug delivery. Narratively, we synthesize a comprehensive overview of the state-of-the-art in nanocarrier technology, providing in-depth insights into the key nanoparticle types presented in the contemporary literature, their fundamental benefits, potential clinical applications, and limitations impeding their development and adoption. We note that there are gaps and opportunities for concerted efforts focused on developing biocompatible and biodegradable nanoparticles, establishing scalable and cost-effective manufacturing processes, and addressing regulatory challenges associated with nanoparticle-based drug delivery systems. These challenges persist despite the immense translational success of nanoparticle-based drug delivery systems and necessitate continued interdisciplinary research and cross-industry collaboration among scientists, clinicians, and regulatory bodies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.